Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Director Sells 77,400 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the sale, the director directly owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Roberto Mignone also recently made the following trade(s):

• On Thursday, November 6th, Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00.

Teva Pharmaceutical Industries Stock Up 0.7%

Shares of TEVA traded up $0.22 during trading hours on Thursday, hitting $30.28. The stock had a trading volume of 8,057,732 shares, compared to its average volume of 11,753,719. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $30.44. The firm has a market capitalization of $34.73 billion, a P/E ratio of 50.47, a price-to-earnings-growth ratio of 1.79 and a beta of 0.67. The firm has a 50 day simple moving average of $24.03 and a 200-day simple moving average of $19.88. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent research reports. Scotiabank initiated coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price objective for the company. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 13th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $31.13.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Teva Pharmaceutical Industries by 51.4% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after buying an additional 11,334,780 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its position in shares of Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after acquiring an additional 9,303,978 shares during the period. Phoenix Financial Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after purchasing an additional 9,094,372 shares during the last quarter. Soundwatch Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $143,533,000. Finally, Wellington Management Group LLP raised its stake in shares of Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after buying an additional 6,878,304 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.